secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fresh Tracks Therapeutics, Inc. (—)
CIK:        0000819050
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001628280-23-032534
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 5.02, 8.01, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fresh Tracks approves dissolution; expects $5-7M distribution ($0.84-$1.17/share)
--------------------------------------------------------------------------------

- Board approved plan to dissolve and liquidate, subject to shareholder vote in Q4 2023.
- CEO Andrew Sklawer terminated without cause effective Oct 2; CFO Albert Marchio appointed CEO/CFO/sole director.
- All three prior directors resign Oct 2; bylaws amended to allow one director.
- Company discontinues all R&D, reduces workforce; estimates cash distribution of $5-7M total.
- Special meeting planned; certificate of dissolution to follow, with Nasdaq delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/0001628280-23-032534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/frtx-20230918.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-032534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer